

## 山東新華製藥股份有限公司 **Shandong Xinhua Pharmaceutical Company Limited**

(a joint stock company established in the People's Republic of China with limited liability)

(Stock Code: 00719)

## Proxy Form for the Second EGM for the Year 2024

(Note 1)

I/We,(Note 1)				
of				(Note 1),
the Ye and ac at No. any ac	the registered holder(s) of	r 2024 at 2:00 p.n vince, the People ny adjournment th	d Extraordinary C  (Note 3), as my/c  n. at the Company 's Republic of Ch	General Meeting for our proxy to attend 's conference room ina (the "PRC") or
	Ordinary Resolutions	For (Note 4)	Against (Note 4)	Abstention (Note 4)
1.	To consider and approve each of the Shandong Lukang Agreement, the China Shandong Agreement, the Hualu Hengsheng Agreement and the Shandong Huatong Agreement (the "CCT Agreements"), their respective annual caps and the continuing connected transactions contemplated thereunder.			
Sharel	nolder's signature:	D	ate:	

## Notes:

- 1. Please insert your full name and address in **BLOCK CAPITALS**.
- 2. Please insert the number and type of shares of the Company registered in your name and to which this proxy form (the "**Proxy Form**") relates. If no such number is inserted, this Proxy Form will be deemed to relate to all the shares in the Company registered in your name (whether alone or jointly with others).
- 3. If any proxy other than the Chairman of the EGM is appointed, cross out "the Chairman of the Second Extraordinary General Meeting for the Year 2024 of the Company (the "EGM"), or", and appoint one or more proxies to attend and vote at the EGM. The proxy appointed need not be a shareholder of the Company. Any alteration made to this Proxy Form must be signed by the person who originally executed this Proxy Form
- 4. If you wish to vote for any resolution, please insert "✓" in the box marked "For". If you wish to vote against any resolution, please insert "✓" in the box marked "Against". If you wish to abstain from voting on any resolution, please insert "✓" in the box marked "Abstention". Failure to make any indication will entitle your proxy/proxies to vote or abstain at his discretion. The number of abstained votes will not be counted as the required majority in favour of any given resolution proposed while the number of abstained votes will be counted into the denominator for the purpose of percentage calculation of the voting.
- 5. This Proxy Form must be signed by you or your attorney duly authorised in writing. Corporations must execute this Proxy Form under common seal or under the hand of any director or attorney duly authorised.
- 6. In order to be valid, this Proxy Form together with any power of attorney or other documents of authorisation (if any) under which it is signed or a notarially certified copy thereof must be lodged with the Secretary to the Board's office of the Company at No. 1 Lutai Ave., Hitech District, Zibo City, Shandong Province, the PRC or to Computershare Hong Kong Investor Services Limited, the Company's H Shares registrar, at Shops 1712–1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong not less than 24 hours before the holding of the EGM.
- 7. In case of joint holders of any share, any one of such joint holders may vote at the EGM, either personally or by proxy, in respect of such shares as if he/she/it is solely entitled thereto. However, if more than one of such joint holders are present at the EGM, personally or by proxy, the vote of the joint holder whose name stands first in the register of members and who tenders a vote, whether in person or by proxy, will be accepted to the exclusion of the votes of other joint holder(s).
- 8. Shareholders or their proxies attending the EGM shall produce their identity documents.
- 9. Completion and return of this Proxy Form will not preclude you from attending and voting at the EGM and any adjournment thereof in person and in such event, this Proxy Form shall be deemed to be revoked.
- 10. Any resolution at the EGM will be taken by poll.
- 11. All references to time herein refer to Hong Kong time.
- 12. Unless the context otherwise requires, capitalised terms defined in this Proxy Form shall have the same meaning as set out in the Company's circular dated 13 November 2024.